These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24729718)

  • 41. Review of meningococcal vaccines with updates on immunization in adults.
    Zahlanie YC; Hammadi MM; Ghanem ST; Dbaibo GS
    Hum Vaccin Immunother; 2014; 10(4):995-1007. PubMed ID: 24500529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease.
    Bröker M; Cooper B; Detora LM; Stoddard JJ
    Infect Drug Resist; 2011; 4():137-47. PubMed ID: 21904459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.
    Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2012 Dec; 8(12):1882-91. PubMed ID: 23032168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial.
    Merino Arribas JM; Carmona Martínez A; Horn M; Perez Porcuna XM; Otero Reigada MDC; Marès Bermúdez J; Centeno Malfaz F; Miranda M; Mendez M; Garcia Cabezas MA; Christoph W; Bleckmann G; Fischbach T; Kolhe D; Van der Wielen M; Baine Y
    Pediatr Infect Dis J; 2018 Jul; 37(7):704-714. PubMed ID: 29620722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.
    Cutland CL; Nolan T; Halperin SA; Kurugol Z; Ahmed K; Perrett KP; Richmond P; Marshall HS; Ceyhan M; Kolhe D; Hezareh M; Van Der Wielen M
    Vaccine; 2018 Mar; 36(14):1908-1916. PubMed ID: 29503112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)
    van der Vliet D; Vesikari T; Sandner B; Martinón-Torres F; Muzsay G; Forsten A; Adelt T; Diaz Gonzalez C; Simko R; B'Chir S; Neveu D; Jordanov E; Dhingra MS
    Epidemiol Infect; 2021 Feb; 149():e50. PubMed ID: 33541457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
    Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
    Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age.
    Vesikari T; Peyrani P; Webber C; Van Der Wielen M; Cheuvart B; De Schrevel N; Aris E; Cutler M; Li P; Perez JL
    Hum Vaccin Immunother; 2020 Jun; 16(6):1280-1291. PubMed ID: 32598244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review.
    Presa J; Findlow J; Vojicic J; Williams S; Serra L
    Infect Dis Ther; 2019 Sep; 8(3):307-333. PubMed ID: 31347097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion.
    Ricci S; Azzari C; Amodio E; Castiglia P
    Expert Rev Vaccines; 2023; 22(1):447-456. PubMed ID: 37144288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Summary of the National Advisory Committee on Immunization's Update on quadrivalent meningococcal vaccines available in Canada.
    Henry B;
    Can Commun Dis Rep; 2015 Apr; 41(Suppl 3):17-18. PubMed ID: 29769963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
    Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of MenACWY-CRM in adolescents in the United States.
    Black S; Block SL
    J Adolesc Health; 2013 Mar; 52(3):271-7. PubMed ID: 23299001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.
    Gasparini R; Tregnaghi M; Keshavan P; Ypma E; Han L; Smolenov I
    Pediatr Infect Dis J; 2016 Jan; 35(1):81-93. PubMed ID: 26398743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.
    Martinón-Torres F; Bertrand-Gerentes I; Oster P
    Expert Rev Vaccines; 2021 Sep; 20(9):1123-1146. PubMed ID: 34365870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2-18 years in Taiwan: results of an open label study.
    Huang LM; Chiu NC; Yeh SJ; Bhusal C; Arora AK
    Vaccine; 2014 Sep; 32(40):5177-84. PubMed ID: 25075804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older.
    Neveu D; Mallett Moore T; Zambrano B; Chen A; Kürzinger ML; Marcelon L; Singh Dhingra M
    Infect Dis Ther; 2023 Oct; 12(10):2367-2386. PubMed ID: 37755671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.